ASCO 2012: Promise Of Drugs for Relapsed/ Refractory Multiple Myeloma (RR MM) To Unfold
Novel products for relapsed/ refractory multiple myeloma (RR MM) and newly diagnosed multiple myeloma (NDMM) will take center stage in this ASCO. These include Celgene’s Pomalidomide (PhIII), Onyx’s Carfilzomib (PhIII), Teva’s Obatoclax, Abbott/PDLI’s Elotuzumab, JNJ’s Siltuximab, GenMab’s Daratumumab, Takeda/Millenium’s MLN9708, Novartis’ Panobinostat, and Senesco’s SNS01-T. In this report, we have analyzed these products based on its safety and efficacy in either RR MM and NDMM pts, presented and topic of discussion at ASCO (oral and poster session) … For more details, please read our report released on May 30th, 2012 on ASCO 2012, titled “Promise Of Drugs for Relapsed/ Refractory Multiple Myeloma (RR MM) To Unfold”.
COMPANIES MENTIONED
